Is there a problem with short-acting beta-2 agonist monotherapy in asthma?

D. Price (Singapore, Singapore)

Source: Virtual Congress 2020 – Airway diseases
Session: Airway diseases
Session type: State of the art session
Number: 4512
Disease area: Airway diseases

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Price (Singapore, Singapore). Is there a problem with short-acting beta-2 agonist monotherapy in asthma?. Virtual Congress 2020 – Airway diseases

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
Source: Eur Respir Rev 2015; 25: 54-64
Year: 2016



What predicts short-acting beta agonist (SABA) monotherapy use in children?
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

Paradoxical bronchoconstriction after administration of beta-2 agonist bronchodilators in COPD patients
Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations
Year: 2021


Efficacy and safety of Long-acting Beta-agonists+Long-acting muscarinic antagonists vs Long-acting Beta-agonists+Inhaled corticosteroids in COPD: a meta-analysis
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017

Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008


Should guidelines be revised for add-on therapy in asthma? A 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and long-acting beta agonists (LABAs) with inhaled corticosteroids (ICS) in primary care
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


Increased doses of inhaled corticosteroids versus addition of long-acting beta2 agonists for treatment of asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010

The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015


Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007


The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Comparison of add-on of leukotriene receptor antagonist vs. long-acting beta2-agonist on FeNO in asthmatic children on regular inhaled budesonide
Source: Eur Respir J 2002; 20: Suppl. 38, 431s
Year: 2002

First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Real-life use and impact of inhaled steroids (ICS) and leukotriene receptor antagonists (LTRA) monotherapy in children with asthma
Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring
Year: 2010

The efficacy and safety of long-acting muscarinic antagonist treatment for COPD
Source: International Congress 2019 – Advances in chronic obstructive pulmonary disease and asthma
Year: 2019


The effect of topical ophthalmic timolol in patients treated for COPD with inhaled beta adrenergic agonist albuterol
Source: Eur Respir J 2006; 28: Suppl. 50, 213s
Year: 2006

Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014


Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013

Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2-adrenoreceptor agonist
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009